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ORIGINAL ARTICLE
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The bacteria that colonize the gastrointestinal tracts of mammals represent a highly selected
microbiome that has a profound influence on human physiology by shaping the host’s metabolic
and immune system activity. Despite the recent advances on the biological principles that underlie
microbial symbiosis in the gut of mammals, mechanistic understanding of the contributions of the
gut microbiome and how variations in the metabotypes are linked to the host health are obscure.
Here, we mapped the entire metabolic potential of the gut microbiome based solely on meta-
genomics sequencing data derived from fecal samples of 124 Europeans (healthy, obese and with
inflammatory bowel disease). Interestingly, three distinct clusters of individuals with high, medium
and low metabolic potential were observed. By illustrating these results in the context of bacterial
population, we concluded that the abundance of the Prevotella genera is a key factor indicating a
low metabolic potential. These metagenome-based metabolic signatures were used to study the
interaction networks between bacteria-specific metabolites and human proteins. We found that
thirty-three such metabolites interact with disease-relevant protein complexes several of which are
highly expressed in cells and tissues involved in the signaling and shaping of the adaptive immune
system and associated with squamous cell carcinoma and bladder cancer. From this set of
metabolites, eighteen are present in DrugBank providing evidence that we carry a natural pharmacy
in our guts. Furthermore, we established connections between the systemic effects of non-antibiotic
drugs and the gut microbiome of relevance to drug side effects and health-care solutions.
The ISME Journal (2013) 7, 730–742; doi:10.1038/ismej.2012.141; published online 22 November 2012
Subject Category: microbe-microbe and microbe-host interactions
Keywords: microbiome; metabolic network; drugs; protein interactions; diseases
Introduction
The adult human gastrointestinal tract is home to
almost 1014 of bacteria, archaea, and eukarya
cells, what is commonly referred to as the gut
microbiome; thus it seems appropriate to view
ourselves as a composite of many species. Our
affiliated microbial partners containX100 times the
number of genes embedded in our Homo sapiens
genome, providing us with a genetic landscape and
functional features we do not have to evolve on our
own (Backhed et al., 2004, 2005). These tens of
trillions of microbes that live in our gastrointestinal
tract represent an anaerobic bioreactor programmed
to synthesize several molecules that direct the
human immune system locally and systematically
(Hooper, 2004). The biosynthetic variability of our
gut microbiota, which remains largely unexplored,
could shape the human physiological phenotypes
and is viewed as a modifier of the host epigenome
(Li et al., 2008). As a matter of fact, the indigenous
metabolic processes coded in the host metagenome
are a source of pharmacologically active secondary
metabolites involved in host metabolic regulation
(Nicholson, 2006; Sonnenburg et al., 2006). Although
we know that the symbiotic gut microbiome has
evolved to exert control over a number of important
mammalian metabolic regulatory functions, little is
understood of the systems level interactions between
the chemical signatures that characterize the organ-
ism-level metabolic status and host cellular pathways.
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The first step in improving our understanding on
how epigenetic or genetic changes that uncouple the
shared evolutionary fate of humans and their
symbiotic bacteria can result in disease, is to
describe the composition of the metabolic network
of microbial communities with respect to the
healthy state. Turnbaugh et al. (2009) have shown
that the gut microbial community structures of adult
monozygotic twin pairs had a degree of similarity
that was comparable to that of dizygotic twin pairs,
and only slightly more similar compared with their
mothers, whereas Palmer et al. (2007) revealed that
gut community assembly during the first year of life
followed a more similar pattern in a pair of dizygotic
twins compared with unrelated infants. This inter-
personal variation in the composition of the human
microbiota implies that studying the role of gut
bacteria in the development of pathophysiology and
as complimentary metabolic machinery for drugs
and diets across a small set of individuals may
inappropriately treat these diverse phenomena as a
single, albeit noisy phenomenon. In contrast, aver-
aging the effects of a disturbance across large cohorts
of individuals with distinct disease phenotypes can
reveal the links between bacterial dynamics and
host physiology and pathology.
These disturbances in a healthy adult microbiota
can be the result of several factors, such as
urbanization, diet or hygiene; however, there is a
major concern that medical therapies may alter the
composition of the human microbiota. Although
antibiotic treatment is typically followed by a
decrease in the diversity of the microbiota
(Jernberg et al., 2007), it is unknown how other
medical treatments might change the microbiota and
deregulate the host immune homeostasis. Recent
studies on drug polypharmacology (Chang et al.,
2010; Ainsworth, 2011; Wang et al, 2011; Yabuuchi
et al., 2011) indicate that many of the known drugs
have more than one target and highlight the need to
undertake a systems level approach to understand
drug efficacy and adverse drug reactions consider-
ing the effect of a molecule in a global physiological
environment, including the gut microbiota.
To get a deeper understanding of the microbial
populations in the human digestive tract and their
interactions with the host, we described the geneti-
cally defined metabotypes from fecal samples of 124
European adults (E3.3 million genes). The cohort is
divided into healthy and obese individual human
adults, as well as inflammatory bowel disease (IBD)
patients (Qin et al., 2010). Even though several
studies have suggested that gut microflora composi-
tion is associated with obesity and IBD (Kau et al.,
2011; Maloy and Powrie, 2011) the elucidation of
the molecular mechanisms underlying microbe–
host reciprocal metabolic interactions is far from
complete. The goals of the present study were to (i)
evaluate the variability in the metabolic potential of
the gut microbiome in healthy individuals based on
variations in the metabolic gene content of the
bacterial population; (ii) apply a systems chemical
biology approach to link the putative meta-metabo-
lome space with the human protein and disease
space and (iii) explore how medical treatments
disturb the bacterial communities, how gut microbes
affect drug metabolism and draw connections
between side effects of drugs and alterations in
human microbiota (Figure 1a).
Materials and methods
Metabolic proteins, reactions and metabolites
Enzymes, reactions and metabolite data were
acquired from MetaCyc 14.6, a database that con-
tains information about experimentally demon-
strated small-molecule metabolic reactions and
pathways, with links to sequences of the responsible
enzymes (Caspi et al., 2010). MetaCyc contains a
total of 9299 unique reactions, of which protein
sequences could be retrieved for 6890. MetaCyc also
contains 8869 metabolites, 8468 of which with
known structure.
Human metagenome data
The metagenome data of the human microbiome are
part of the Metagenomics of the Human Intestinal
Tract (MetaHit) project (Qin et al., 2010). The data
consist of gene sequences, distribution of genes
among individuals (healthy samples¼ 53, obese
samples¼ 46, IBD samples¼ 10) and metadata for a
subset of the samples, describing other non-genomic
characteristics. The raw Illumina read data of all
124 samples have been deposited in EBI, under the
accession ERA000116. The contigs and gene set are
available to download from EMBL (http:///www.
bork.embl.de/Barumugam/Qin_et_al_2010/) and BGI
(http://gutmeta.genomics.org.cn) websites.
Linking MetaHit with MetaCyc database
All nucleotide sequences from the MetaHit FASTA-
files were given in their respective reading frame
and could thus be translated directly to the amino
acid sequences. The link between the MetaHit data
and the MetaCyc database was initially established
by finding homolog proteins using the BLAST-Like
Alignment Tool (BLAT) (Kent, 2002). Two proteins
were considered homologs if there was at least 80%
coverage of the MetaHit protein sequence with 85%
identity (amino acid level). A set of metabolic
proteins and the respective metabolic network were
assigned to each sample. For the metabolic proteins
that were found in470% of the samples, the KEGG
IDs of the respective metabolic reactions were
retrieved and visualized using iPATH (Yamada
et al., 2011). The abundance per sample of each
metabolic gene is not depicted in the iPATH
visualization.
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Species diversity
Taxonomical information regarding each MetaHit
sequence aligned to a MetaCyc sequence was
acquired by aligning all MetaHit sequences to
sequences of known origin, using 90% identity
threshold (nucleotide level), describing classes ran-
ging from super kingdom to strain (Qin et al., 2010).
Of the 3.3 million sequences of the non-redundant
database, almost 500 000 were not directly asso-
ciated to species.
a
c
d e
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Clustering and statistical analysis
The distance between samples was measured from
their metabolic reaction profile using a binary
matrix (‘1’: the reaction is present in an individual,
‘0’: the reaction is absent). The similarity between
two samples was measured by the Tanimoto coeffi-
cient (Tc). The Tc gives a similarity value based on
the overlap and size of the bit strings of the two
samples under examination (Jonsdottir et al., 2005).
Then the distance between samples is simply
calculated as 1 minus Tc. The clustering of the
samples was performed using hierarchical cluster-
ing with Ward’s method (Ward, 1963).
For each reaction, we calculated the mean
abundance over all samples, where the reaction
was present (for example, mean for healthy, obese
and IBD). Subsequently, we calculated the log2-fold
change between healthy and obese, and between
healthy and IBD, respectively. We kept reactions
with a log2-FC o 1 or 4þ 1, and we ended up
with 64 reactions for the obese samples and 128 for
the IBD samples. We then performed a Wilcoxon
rank test (data is sparse, and therefore t-tests are not
suitable) on these reactions and P-values were
adjusted using the false discovery rate (Benjamini–
Hochberg).
Disease genes and complexes
Data on disease-relevant protein complexes
were retrieved from our in-house database (Lage
et al., 2008) (http://cbs.dtu.dk/cgi-bin/phecomplex/
index.pl, last accessed on 31 August 2011), where
complexes are linked to tissues through RNA
expression data derived from 73 healthy tissues
from the Novartis Research Foundation Gene
Expression Database (www.gnf.org). A positive
z-score indicates that the genes participating in a
complex are expressed in the particular tissue at a
higher level than the average gene of this tissue. The
database consists of a list of 1524 protein complexes,
assembled by 5202 unique proteins, connected
through 45 662 unique interactions. The complexes
are mapped to 1054 OMIM diseases. For 346
complexes the z-score for each of the 73 tissues is
available. More information for the methodology on
tissue specificity of disease complexes could be
found in Lage et al. (2008).
Human metabolic network
In order to construct a subset of MetaCyc containing
only non-human metabolites, human metabolomics
data were acquired from the Homo sapiens Recon 1,
a comprehensive literature-based genome-scale
metabolic reconstruction of the global human meta-
bolic map (Duarte et al., 2007). H. sapiens Recon 1 is
part of the BIGG database (Schellenberger et al.,
2010). All structures from MetaCyc and H. sapiens
Recon 1 were first converted to Canonical SMILES
using Open Babel (O’Boyle et al., 2011). SMILES
(Simplified Molecular Input Line System) is a line
notation for representing structures of small mole-
cules. The generated SMILES is not unique for a
given structure, thus, canonicalization involves the
adoption of certain rules, which produce one
generic SMILES among all valid possibilities
(http://www.daylight.com/dayhtml/doc/theory/the-
ory.smiles.html). Metabolites with identical Cano-
nical SMILES, which were present in both MetaCyc
and H. sapiens Recon 1, were subsequently removed
from the former and the remaining ones consisted
the list of non-human metabolites.
Drugs and drug-target data
Small-molecule drug and target data were acquired
from DrugBank (DB) v.3 (Knox et al., 2011) and the
Therapeutic Target Database (TTD) 4.3.02 (Chen
et al., 2009). DB contains information for 6708 drugs
(including 1437 approved, 5086 experimental, 83
nutraceuticals and 134 protein/peptide drugs)
linked to 4229 non-redundant targets. Small-mole-
cule structures, as SMILES strings, were obtained for
6628 small molecules, while the sequences of the
drug targets were retrieved as FASTA files (available
for 4050 targets). The TTD contains information for
17 816 drugs (including approved, clinical, experi-
mental and antisense drugs) linked to 2025 targets
(including successful, clinical, discontinued and
research targets). Structures were downloaded for
14 783 small molecules as MOL-files and were
converted to SMILES strings using Open Babel.
FASTA-files for 1502 protein targets were also
available at the TTD website. After merging of the
two datasets and removal of duplicates, the final list
consisted of 19 917 unique small molecule struc-
tures and 4595 unique drug targets.
Figure 1 The genetically defined metabotypes of the bacterial communities in the gut of healthy individuals. (a) The present study
focuses on the evaluation of: (1) the interactions between small molecules (metabolites) produced by the microbiome and human
proteins, and (2) the interactions between drug molecules and bacterial proteins. (b) The frequency of each of the 1490 metabolic
reactions (red: essential reactions, blue: non-essential) that were assigned to the microbiome of the healthy individuals. The frequencies
are given as both: (1) total number of reactions for a given frequency, represented by the bar width, and (2) density for essential and non-
essential reactions for a given frequency. (c) Visualization of the most common (present in470% of the samples) metabolic reactions (59
reactions) of the group of healthy individuals. Glycolysis, pyruvate metabolism, fatty acid metabolism, amino acid and nitrogen
metabolism were the most conserved parts of the metabolic network. (d) The three distinct groups formed by clustering the healthy
individuals based on a binary representation of their microbiome metabolic profile. The three clusters are characterized by high (736–
1395), medium (254–758) and low (34–195) number of metabolic reactions. (e) Distribution of reaction counts in healthy samples
dominated by the Bacteroides, Prevotella, and Ruminococcus genera (Arumugam et al., 2011).
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The similarity between the small molecule drugs
and bacterial metabolites was accessed by the
Tanimoto coefficient. Two molecules were consid-
ered similar when they fulfilled both the following
criteria: (i) TcX0.85, and (ii) at least one common
protein interaction partner in ChEMBLdb.
Results
Metabolic individuality in the healthy human
microbiome
To evaluate the metabolome profile of the gut of
healthy individuals we defined the metabolic
capacity of the bacterial populations by linking the
MetaHIT protein sequences to the MetaCyc database
(Caspi et al., 2010) for each individual. We could, in
this manner, retrieve all the MetaHit genes (from
now on called ‘metabolic genes’) coding for proteins
that are part of a metabolic pathway (from now on
called ‘metabolic proteins’). Using strict criteria, two
proteins were considered to be homologs when
they shared 85% identity and at least 80% coverage,
and a total of 3775 MetaHIT sequences accounting
for 1490 metabolic reactions were retrieved
(Supplementary Table S1). We should emphasize
here that the metabolome profile assigned to each
individual is solely based on genomic data that
indicate the metabolic potential of the bacterial
population with no further evidence that the
detected genes are actually expressed to produce
the metabolites. A binary presence/absence (1/0)
matrix was constructed using these 1490 metabolic
reactions for the healthy samples. This matrix
revealed a large variation in the total number of
metabolic reactions that were assigned in the
microbiome of each healthy individual. To investi-
gate further this metabolic diversity in connection to
the composition of the microbiome, we visualized
the frequency of each metabolic reaction per
individual taking into account its essentiality.
Reactions were divided into essential and non-
essential (Figure 1b) based on the Database of
Essential Genes (Zhang and Lin, 2009) (DEG) 6.5
(http://essentialgene.org). By aligning the sequences
from 18 prokaryotes in DEG to the MetaHIT
sequences we retrieved 310 protein hits responsible
for 425 essential metabolic reactions. Assigning a
metabolic reaction as essential in our metagenome
data should be always interpreted with caution so as
not to neglect the symbiotic relationships in the
bacterial population. Nevertheless from Figure 1b it
is apparent that non-essential metabolic reactions
have lower frequency among individuals compared
with essential reactions (P-valueo2.2 1016 using
Welch t-test). To capture a snapshot of the highly
conserved among healthy individuals metabolic
network, we visualized the metabolic reactions with
frequency 470% using iPath2.0 (http://pathways.
embl.de/). The parts of the microbiome metabolism
that show a higher conservation among individuals
are glycolysis and pyruvate metabolism, fatty acid
metabolism, amino acid and nitrogen metabolism
(Figure 1c).
Subsequently, the genetically defined metabotypes
were visualized in a heat map (Figure 1d) where the
distance between individuals is measured from their
metabolic reaction profile using the binary matrix
described above. Interestingly, three distinct clusters
of healthy individuals with high, medium and low
metabolic potential were observed. The larger group
was the one with high metabolic potential, harboring
between 736–1395 metabolic reactions. The number of
reactions for the medium and low metabolic potential
groups were 254–758 and 34–195, respectively. We
have further confirmed that the clusters of metabolic
potential are not the outcome of correlations with the
general richness of the sample, or with sequencing
depth (Supplementary File S1).
To illustrate these results in the context of
bacterial population, we studied in what degree
the variability in the metabolic potential of indivi-
duals is correlated with the abundance levels of the
Bacteroides, Prevotella and Ruminococcus genera in
each sample (Arumugam et al., 2011). If we attempt
to draw direct connections between the abundance
of the three genera and the richness of the metabolic
network based on Figure 1e, a high correlation is
observed only for the Prevotella genera; Prevotella
shows strong presence in samples with low meta-
bolic potential and it becomes virtually absent in
samples with high number of metabolic reactions.
However, we should keep in mind that our correla-
tions between the three genera and metabolic
potential are based solely on genomic data.
Generating connections of ‘non-human’ metabolites,
protein complexes and diseases
To uncover potentially produced meta-metabolites
that may have a significant contribution to health
maintenance, we sought interactions between
human proteins and bacterial metabolites that are
not part of the human metabolic network. To create
Figure 2 The interactome space of the 33 ‘non-human’ metabolites with the human proteome. (a) A total of 195 MetaHit sequences
(non-redundant) are involved in reactions in which these 33 metabolites participate. (1) Taxonomy distribution (top 20 species) for the
MetaHit sequences (1091 non-redundant) involved in all metabolic reactions, (2) available taxonomy distribution for 56 of the 195
MetaHit sequences. (b) Heat map showing the disease space (given as OMIM IDs) targeted by the 33 metabolites that can be synthesized
or degraded only by the gut microbiome. Information in parenthesis shows whether a metabolite participates in an irreversible reaction
(as substrate (S) or a product (P)) or in a reversible reaction (S and P). When available, the Anatomical Therapeutically Classification code
was retrieved from DrugBank. (c) The tissue specificity (given as a z-value) of the disease protein complexes that interact with
metabolites with high binding affinity (Kip1 mM). Hierarchical clustering was performed using Euclidean distances according to Ward’s
method. Detailed information for the protein complex IDs is provided in Supplementary Table S4.
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this set of metabolites we overlaid the putative gut
microbiome metabolism with the Homo sapiens
Recon 1 (Duarte et al., 2007) metabolic model. We
obtained a set of 482 metabolites with known
structure, which can be potentially synthesized or
degraded only by the gut bacteria. This study
Tissue
1.5 1.0 0.5 0.0 0.5 1.0 1.5 2.0
a1 2
b
c
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revealed at the same time a significant overlap
between the human and the bacterial metabolic
capacity (376 shared metabolites), comparable to the
number of human-specific metabolites (472 metabo-
lites). The set of 482 metabolites that cannot be
produced or metabolized by humans (‘non-human’
metabolites) was the base for the subsequent
analysis. ChEMBLdb (Gaulton et al., 2011), a
manually curated database of bioactive molecules,
was used for generating an interactome map of the
‘non-human’ metabolites and the human proteome
space. From the 62 metabolites that were linked to
the human proteome (Supplementary Table S2), and
after filtering for small organic molecules, 33 were
found to be associated with a disease-relevant
protein complex, while 18 of them were present in
DrugBank (Knox et al., 2011) as experimental drugs.
In the metabolic reactions of the metagenome, in
which the ‘non-human’ metabolites are involved,
five appear as substrates (S), eight appear as
products (P), and the rest appear as both a substrate
and a product (S and P) (Figure 2b). The taxonomy
of genes encoding the bacterial enzymes involved in
these reactions revealed Escherichia coli, Klebsiella
pneumonia, Enterobacter cloacae (and E. cancer-
ogenus), Shigella sp. and Citrobacter rodentium as
the most efficient producers/consumers (Figure 2a).
However, we should keep in mind that linking
sequences with species was possible for only one-
third of the enzymes.
The interactions of the ‘non-human’ metabolites
with disease complexes were established using an
in-house database, which includes 2227 unique
proteins that have been associated with a disease
OMIM (Online Mendelian Inheritance in Man) ID
through data mining (Lage et al., 2008; Figure 2b).
Disease protein complexes involved in squamous
cell carcinoma, Li-Fraumeni syndrome, lung cancer
and bladder cancer were associated with 410 ‘non-
human’ metabolites each. Drug metabolism disor-
ders were also ranked highly in the list, as several
metabolites interact with complexes that include
enzymes of the cytochrome P450 superfamily
involved in the metabolism of drugs and other
xenobiotics (Supplementary Table S3). Metabolites
quercetin and menadione that were found to interact
with disease protein complexes associated with a
large number of OMIM IDs, seem to have a
significant role in the host-bacterial mutualism.
Along with these two ‘non-human’ metabolites,
hydroquinone and S-carboxylmethyl-D-cystein
formed a cluster sharing many of the disease IDs.
Quercetin, menadione and S-carboxymethyl-D-
cysteine participate in reversible reactions offering
a higher degree of flexibility for regulating their
concentrations in the gut, whereas hydroquinone
appears as product of an irreversible reaction,
according to MetaCyc.
Figure 2c illustrates the tissue specificity (given as
a z-value) for the disease complexes, where at least
one member protein is targeted with high affinity by
one of the ‘non-human’ metabolites (detailed infor-
mation for the disease complex IDs is given in
Supplementary Table S4). Five metabolites, namely
quercetin, erythronate-4-phosphate, D-glucono-1,
5-lactone, 50,500-diadenosine triphosphate and
hydroquinone, were associated with disease com-
plexes, because of experimental binding activity to a
member of the complex of Kip1mM, which is a
common threshold when considering efficient,
small compound ligands (Overington et al., 2005).
A cluster on the lower left part of this figure caught
our attention, with 13 disease complexes related
with different types of cancer that are highly
expressed in cells and tissues involved in the
signaling and shaping of the adaptive immune
system (such as NK cells, B cells, dendritic cells,
thymus, monocytes). Quercetin shows high affinity
interactions with 11 of the complexes, whereas
hydroquinone and D-glucono-1,5-lactone interact
with one complex each. The protein complex
targeted by hydroquinone is involved in DNA repair
(GO:0006281, P-valuep5.10e 15) supporting evi-
dence that this metabolite acts as an inducer of
cytogenetic changes and DNA hypomethylation (Ji
et al., 2010), whereas the protein complex targeted
by D-glucono-1,5-lactone is involved in transcription
regulation (GO:0045449, P-valuep5.29e 22).
Modulation of obesity and IBD by the gut microbiota
The MetaHIT cohort also contains samples from
patients with IBD as well as individual fat percen-
tage values for some samples, which can be used to
group people as obese, allowing us to test if
variations in the gut metabotypes have a role in
the progression of these diseases. Following the
same approach as the one used for the healthy
individuals, we defined the metabolic network of
the bacterial community for obese (1487 reactions)
and IBD patients (1480 reactions). When clustering
the samples for obese and IBD patients, based on
binary data, we observed a similar trend as for the
healthy individuals with three clusters of high,
medium and low metabolic potential (data not
shown). As the binary data could not reveal any
significant differences in the metabolic potential
between healthy and disease samples, we evaluated
the abundance of the metabolic reactions per
individual in each group (healthy, obese and IBD).
The term abundance corresponds to the frequency of
the sequences coding for each metabolic protein
within the complete set of metabolic genes of the
individual. In contrast to the binary data, attempting
to cluster the samples of each group based on the
abundance values resulted in no distinct clusters.
Supplementary Figure S1 shows the most abundant
metabolic reactions for healthy, obese and IBD
samples. N-succinyl ornithine carbamoyl transferase
and GDP-mannose 4,6 dehydratase were the most
abundant metabolic genes not only in healthy but
also in obese and IBD samples. When comparing the
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top-20 most abundant metabolic genes between the
different groups very few differences were observed.
In the comparison of the healthy against the other
two groups, 3-aminobutyryl-CoA ammonia lyase,
N-acetylhexosamine 1-kinase and formate C-acetyl-
transferase were the only reactions that did not
appear in the top-20 of obese individuals, while
pyruvate synthase, dimethylmaleate hydratase,
acetyl-CoA-acetyl transferase, pyridoxal 50-phos-
phate synthase (glutamine hydrolyzing) and hydro-
gensulfite reductase are the ones absent in the IBD
top-20 most abundant metabolic genes.
In order to find statistically significant differences
in the metabolic potential between healthy, obese
and IBD samples, we applied a Wilcoxon signed-
rank test, and used false discovery rate correction for
multiple testing. The abundance of only two meta-
bolic genes was found to be significantly different
(P-valueo0.05, both lower abundant in IBD indivi-
duals). The first reaction (E.C.1.3.5.4) is catalyzed by
fumarate reductase, whereas the second one is the
oxidation of menadiol by quinol monooxygenase
yielding menadiole, superoxide and Hþ . As there is
an increasing focus on oxidative stress as potential
etiological factor and/or triggering factor in Crohn’s
disease (Iborra et al., 2011), it was interesting to find
a reaction containing superoxide significantly dif-
ferent between healthy and IBD patients. While in
the literature there are metabolomic-based studies
performed in humans or model systems that have
reported differences in the concentration of specific
metabolites between healthy and non-healthy
(obese, IBD) individuals (Waldram et al., 2009;
Turnbaugh et al., 2010; Le Gall et al., 2011;
Ponnusami et al., 2011), our analysis points out
that these differences are not the result of genomic
variability in the metabolic potential of the gut
microflora. The analysis of transcripts would be the
next natural step of the present study, in order to
investigate whether there is a uniform functional
pattern in healthy, obese and IBD samples or the
differences in the metabolome level observed in
other studies are the result of differences at the
mRNA level.
Drug effects on host-microbiome mutualism
To identify drug treatments that are affected the
most by the gut microbiome and vice versa, we
followed two approaches: (i) we studied the chemi-
cal similarity between all drug molecules present in
DrugBank and the metabolites of the metabolic
network of healthy individuals. A drug and a
compound were considered similar if they had a
Tanimoto coefficientX0.85 and shared at least one
known protein interactor in ChEMBLdb. (ii) We
evaluated the sequence similarity (90% similarity
and 80% coverage) of the drug targets with the
metabolic and non-metabolic proteins of the meta-
genome of healthy individuals. In total, 603 experi-
mental and approved drugs (among them 42
antibiotics) were predicted to perturb 515 unique
metabolic reactions (64 drugs linked to metabolic
reactions based on drug-metabolite chemical simi-
larity and 556 drugs based on target homology).
From these metabolic reactions, 161 are essential
reactions (DEG 6.5) (Figure 3a). Interestingly, 16
experimental drugs and 5 approved drugs are
identical to metabolites that act as substrates in the
microbiome metabolic network, indicating that their
therapeutic activity is potentially affected by bacter-
ial metabolism. Looking into the non-metabolic
targets of drugs, based on the sequence similarity
of the drug target and the MetaHit sequences, we
found 334 drugs (among them 60 antibiotics) that
could potentially modulate the activity of 495
proteins (Figure 3b) of the bacterial community
(170 essential proteins). From the above drug–
microbiome interactions there were several notable
cases. Tobramycin interacts with two non-metabolic
proteins, which are both assigned as essential.
Tobramycin is an antibiotic used to treat various
types of bacterial infections and shows diarrhea
and abdominal pain as highly common side effects
(www.sideeffects.embl.de). Olanzapine and aripir-
pazol were shown to interact each with one non-
metabolic protein of the gut metagenome. These two
antipsychotic drugs show diarrhea, dyspepsia, con-
stipation and gain weight (only olanzapine) as
common side effects. Cytarabine, an anticancer
drug, targets five metabolic proteins (one of them
essential) of the bacterial metabolic network.
According to SIDER constipation is a common side
effect associated with this treatment. In Table 1, we
present the 18 drugs and their respective Anatomi-
cal Therapeutic Chemical Classification codes with
the most relevant, to the gut microbiome, side effects
(diarrhea, flatulence and so on).
Discussion
The role of the human intestinal microbiome in
metabolizing dietary constituents and protecting the
host against pathogens is crucial to human health
(Ley et al., 2008). Analysis of genomic and metage-
nomic sequences has produced gene catalogs with
protein families involved in the predominant func-
tions of the gut bacteria (Qin et al., 2010; Turnbaugh
et al., 2010). However, currently lacking is a large-
scale systematic analysis of the complex chemical
space generated by these bacteria and the interaction
with the human proteome. By defining the geneti-
cally defined metabotypes of 4120 individuals, we
concluded that independent of healthy or diseased
samples, the individuals are clustered as high,
medium or low metabolic potential. Further to this,
Prevotella genera appear to be highly sensitive to the
complexity of the metabolic chemical space.
A comparison of the metagenome metabolic net-
work with the human metabolic network revealed a
large number of metabolites that appear as reactants
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ab
Figure 3 Drug–metagenome interactions. (a) A network of interactions between drug molecules (circles) and metabolic reactions
(squares) in healthy individuals. A drug is connected with a metabolic reaction if (i) it is chemically similar with a metabolite that
appears as reactant and (ii) the drug and the metabolite share at least one protein interactor in ChEMBLdb. Red font indicates essential
reactions and green font indicates antibiotics. (b) A network of interactions between drug molecules (circles) and non-metabolic proteins
(squares) in healthy individuals. A drug is connected with a protein if the drug target and the metagenome protein are homologs (90%
similarity and 80% coverage). Red font indicates essential reactions and green font indicates antibiotics.
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only in the bacterial metabolism. The finding that
from this set of metabolites, 18 are present in
DrugBank provides evidence that we carry a natural
pharmacy in our guts. In addition, 15 other ‘non-
human’ metabolites were found to interact with a set
of human protein complexes associated with a wide
spectrum of diseases. For example quercetin, a
flavonoid compound that is widely distributed in
nature, and menadione, a vitamin precursor of K2,
were found to interact with disease protein com-
plexes associated with a large number of OMIM IDs.
Although there are no official health claims granted
to quercetin, several studies have been conducted
that report reduction of systolic blood pressure and
plasma oxidized low-density lipoprotein concentra-
tions in overweight subjects with a high cardiovas-
cular disease risk phenotype (Egert et al., 2009),
potential anti-obesity effects (Yang et al., 2008) and
protection from colon and prostate cancer
(Senthilkumar et al., 2011; Bae et al., 2012). Using
here compound-protein interaction data we asso-
ciated quercetin with disease protein complexes
involved in both obesity and IBD. Menadione is a
clinically important chemotherapeutic agent used in
the treatment of leukemia and other types of cancer
(Laux and Nel, 2001; Matzno et al., 2008). Due to
adverse effects associated with it, menadione is used
as nutritional supplement only in few developing
countries, but is still used in many countries as
inexpensive micronutrient for livestock. Under-
standing the regulation of the metabolic pathways
in which the above two and the rest of the 33
metabolites are involved, and monitoring their
actual concentration in healthy and disease indivi-
duals, could guide us to rationally design diets that
promote host homeostasis. However, as genomic
data provide only a blueprint or inventory of genes
encoding enzymes without any proof of function-
ality, meta-transcriptomic or meta-metabolomic ana-
lysis is necessary before we attempt to shape the
bacterial metabolic network activity to benefit the
host. Especially, the power of meta-metabolomic
analysis for establishing direct links between altera-
tions in the gut microbiome and human host
responses has been demonstrated in several studies.
Martin et al. (2010) applied microbial profiling of
fecal contents in four groups of animals to study
dietary-specific modulation of microbial popula-
tions and a different profile of amino acids and
SCFAs was observed upon modification of the
dietary pattern (glucose–lactose mix) in conven-
tional and non-conventional animals. In another
notable study Yap et al. (2008) were the first to show
that major perturbation of microbiome metabolites
manifests with changes to the host’s systemic
metabolic phenotype.
Antibiotics have been used effectively for over
half a century to treat bacterial infections; however,
it is widely accepted that they can also markedly
affect the composition of the microbiota. Although
the effect of antibiotics is short term, as typically
most families and genera of gut microorganisms
return to typical levels within weeks of exposure,
there is no information on how the bacterial
communities are affected by other classes of drugs,
especially drugs with long-term use from the human
host. From the computational analysis applied in
our study there are indications that antibiotics are
not the only therapeutic treatment that can result in
a dysregulation of the symbiosis between the host
and its microbiota. Antipsychotic and anticancer
drugs were also found to potentially interact with
bacterial proteins, and these interactions might
explain observed side effects, such as diarrhea and
constipation; however, experimental evidence is
required to validate these observations. Zheng
et al. (2011) have determined the global metabolic
effects and dynamic changes of 223 fecal metabo-
lites in antibiotic-treated rats and revealed altera-
tions in metabolic systems not previously correlated
with antibiotics. In parallel, Jakobsson et al. (2010)
analyzed the 16S rRNA gene using 454-based
pyrosequencing and terminal-restriction fragment
length polymorphism of bacterial populations in
human fecal samples after antibiotic administration
and revealed marked ecological disturbances that
naturally influence the abundance of specific meta-
bolites. These are just a few of the experimental
approaches that could be used for studying experi-
mentally drug–microbiome interactions. In contrast
to antibiotics, antipsychotic and anticancer drugs
are long-duration treatments; therefore a mechan-
istic understanding of their side effects is of utmost
importance.
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